Simin Almasi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Simin Almasi has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Afsaneh Zeinalzadeh
Department of Physical Therapy, School of Paramedical and Rehabilitation Sciences, Mashhad University of Medical Sciences, Mashhad, Iran
2 shared publications - Mahyar Salavati
Department of Physiotherapy, University of Social Welfare and Rehabilitation Sciences, Koodakyar Ave, Daneshjoo Blvd, Evin, Tehran, Iran
2 shared publications - Salman Nazary-Moghadam
Department of Physical Therapy, School of Paramedical and Rehabilitation Sciences, Mashhad University of Medical Sciences, Mashhad, Iran
2 shared publications - Abdolmohammad Ranjbar
Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
1 shared publication Ahmad Reza Jamshidi
Rheumatology Research center, Tehran University of medical sciences, Tehran, Iran
1 shared publicationAli Khalooei
1 shared publication
Latest Publications
- Open Access
- 30 November 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (23) , 3575
Myocardial and Vascular Involvement in Patients with Takayasu Arteritis: A Cardiovascular MRI Study
We aimed to explore the cardiovascular magnetic resonance (CMR) of Takayasu arteritis (TA) and its cardiovascular complications. CMR was conducted on 37 TA patients and 28 healthy individuals. We evaluated the CMR findings and adverse cardiovascular complications at the time of the CMR (ACCCMR). After 8 to 26 months, the major adverse cardiac and cerebrovascular events (MACCEs) were evaluated. The TA included 25 women (67.6%), aged 36 ± 16 years old, and 28 age- and sex-matched healthy controls. Left ventricular (LV) ejection fraction was significantly lower in the TA group than in the control group (51 ± 9% vs. 58 ± 1.7%; p < 0.001). Aortic mural edema was present in 34 patients (92%) and aortic mural hyperenhancement in 36 (97%). Left ventricular global longitudinal strain (LVGLS) was significantly lower in the TA group (median [interquartile range] = 13.70 [3.27] vs. 18.08 [1.35]; p < 0.001). ACCCMR was seen in 13 TA patients (35.1%), with the most common cardiac complication being myocarditis (16.2%). During a median follow-up of 18 months (8–26 months), nine patients developed MACCEs, of which the most common was cerebrovascular accident in five (13.5%). The LVGLS of the CMR had the strongest association with complications. Myocardial strain values, especially LVGLS, can reveal concurrent and future cardiovascular complications in TA patients.
- 30 November 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (23) , 3575
Open AccessMyocardial and Vascular Involvement in Patients with Takayasu Arteritis: A Cardiovascular MRI Study
We aimed to explore the cardiovascular magnetic resonance (CMR) of Takayasu arteritis (TA) and its cardiovascular complications. CMR was conducted on 37 TA patients and 28 healthy individuals. We evaluated the CMR findings and adverse cardiovascular complications at the time of the CMR (ACCCMR). After 8 to 26 months, the major adverse cardiac and cerebrovascular events (MACCEs) were evaluated. The TA included 25 women (67.6%), aged 36 ± 16 years old, and 28 age- and sex-matched healthy controls. Left ventricular (LV) ejection fraction was significantly lower in the TA group than in the control group (51 ± 9% vs. 58 ± 1.7%; p < 0.001). Aortic mural edema was present in 34 patients (92%) and aortic mural hyperenhancement in 36 (97%). Left ventricular global longitudinal strain (LVGLS) was significantly lower in the TA group (median [interquartile range] = 13.70 [3.27] vs. 18.08 [1.35]; p < 0.001). ACCCMR was seen in 13 TA patients (35.1%), with the most common cardiac complication being myocarditis (16.2%). During a median follow-up of 18 months (8–26 months), nine patients developed MACCEs, of which the most common was cerebrovascular accident in five (13.5%). The LVGLS of the CMR had the strongest association with complications. Myocardial strain values, especially LVGLS, can reveal concurrent and future cardiovascular complications in TA patients.
- Open Access
- 30 September 2022
- Published by Convin SA in Mediterranean Journal of Rheumatology
- Vol. 33 (3) , 311-315
Prevalence of COVID-19 in Different Types of Collagen Vascular Diseases and its Relationship with Drugs Used in these Patients
Objectives: The outcome of COVID-19 disease in vascular collagen patients and its comparison with other infected people in the community, are not fully understood yet. In this study, we examined whether COVID-19 is more prevalent in these patients, or it is associated with a higher severity of their involvement. Methods: This was a retrospective study performed between August and December 2020 on vascular collagen patients referred to the rheumatology clinic of Firouzgar Hospital. Accordingly, the patients were examined for COVID-19. As well, the prevalence of the disease in these patients and its relationship with age, sex, type of disease, medications used, blood type, and history of influenza vaccine were then evaluated. Results: Among the total 748 patients, 574 (76.6%) subjects were women, and 174 (23.3%) subjects were men. The mean age of the patients was 47.46 years old; the minimum age was 16 years old, and the maximum age was 82 years old. A total of 60 patients (8%) suffered from COVID-19 and its highest incidence rate was related to rheumatoid arthritis (36.7%) and the lowest one was for vasculitis (1.7%). Notably, 12.5% of the patients who did not suffer from COVID-19, were vaccinated against influenza (p-value = 0.54). In this regard, a significant relationship was found between COVID-19 incidence and previous existence of interstitial lung disease (ILD) (p-value = 0.017). Conclusions: The incidence of COVID-19 in vascular collagen patients was not higher than that of the general population and there was no significant relationship among the incidence of COVID-19 and its severity and the type of disease, the drug, and blood group of vascular collagen patients. Since so far, no studies have been performed on the effect of DMARD drugs on the incidence and severity of Covid 19 disease in collagen patients, it seems that if this study can be done with a larger sample size, better results will be obtained.
- 30 September 2022
- Published by Convin SA in Mediterranean Journal of Rheumatology
- Vol. 33 (3) , 311-315
Open AccessPrevalence of COVID-19 in Different Types of Collagen Vascular Diseases and its Relationship with Drugs Used in these Patients
Objectives: The outcome of COVID-19 disease in vascular collagen patients and its comparison with other infected people in the community, are not fully understood yet. In this study, we examined whether COVID-19 is more prevalent in these patients, or it is associated with a higher severity of their involvement. Methods: This was a retrospective study performed between August and December 2020 on vascular collagen patients referred to the rheumatology clinic of Firouzgar Hospital. Accordingly, the patients were examined for COVID-19. As well, the prevalence of the disease in these patients and its relationship with age, sex, type of disease, medications used, blood type, and history of influenza vaccine were then evaluated. Results: Among the total 748 patients, 574 (76.6%) subjects were women, and 174 (23.3%) subjects were men. The mean age of the patients was 47.46 years old; the minimum age was 16 years old, and the maximum age was 82 years old. A total of 60 patients (8%) suffered from COVID-19 and its highest incidence rate was related to rheumatoid arthritis (36.7%) and the lowest one was for vasculitis (1.7%). Notably, 12.5% of the patients who did not suffer from COVID-19, were vaccinated against influenza (p-value = 0.54). In this regard, a significant relationship was found between COVID-19 incidence and previous existence of interstitial lung disease (ILD) (p-value = 0.017). Conclusions: The incidence of COVID-19 in vascular collagen patients was not higher than that of the general population and there was no significant relationship among the incidence of COVID-19 and its severity and the type of disease, the drug, and blood group of vascular collagen patients. Since so far, no studies have been performed on the effect of DMARD drugs on the incidence and severity of Covid 19 disease in collagen patients, it seems that if this study can be done with a larger sample size, better results will be obtained.
- Open Access
- 1 April 2018
- Published by DoNotEdit in Rheumatology Research
- Vol. 3 (2) , 59-62
The prevalence and type of pulmonary involvement in ankylosing spondylitis
Ankylosing spondylitis (AS) is a chronic and inflammatory disease that affects the spinal column and peripheral joints. Pulmonary manifestations in patients with ankylosing spondylitis are rare and usually asymptomatic and include restrictions from fibrobullous apical disease, chest wall disease, spontaneous pneumothorax, and obstructive sleep apnea. This cross-sectional study was performed on 60 patients with AS. All patients fulfilled the modified New York criteria, 1984. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI), CRP, and ESR were measured in all patients. All patients were visited by a rheumatologist and a pulmonologist, and pulmonary function test (PFT) and chest x-ray (CXR) were performed. High-resolution computed tomography (HRCT) was performed only in patients who had abnormal results in clinical examination, PFT, or CXR. Overall, 50 patients had normal CXR (83.3%) and 10 patients (16.7%) had abnormal CXR, including reticulonodular (3.3%), atelectasis (3.3%), and lucency (3.3%). Of the 14 cases that were HRCT, only 8 (57.1%) had abnormal lung CT scans. The Pulmonary Function Test (PFT) was taken from all patients, and 15 (25%) patients had abnormal results, 11 (18.3%) had a restrictive pattern, and 4 (6.7%) had an obstructive pattern. The incidence of lung involvement in patients with AS in this study is similar to that of other studies (16%); in most cases, the lung involvement is of the restrictive pattern. Lung involvement in these patients may be asymptomatic.
- 1 April 2018
- Published by DoNotEdit in Rheumatology Research
- Vol. 3 (2) , 59-62
Open AccessThe prevalence and type of pulmonary involvement in ankylosing spondylitis
Ankylosing spondylitis (AS) is a chronic and inflammatory disease that affects the spinal column and peripheral joints. Pulmonary manifestations in patients with ankylosing spondylitis are rare and usually asymptomatic and include restrictions from fibrobullous apical disease, chest wall disease, spontaneous pneumothorax, and obstructive sleep apnea. This cross-sectional study was performed on 60 patients with AS. All patients fulfilled the modified New York criteria, 1984. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI), CRP, and ESR were measured in all patients. All patients were visited by a rheumatologist and a pulmonologist, and pulmonary function test (PFT) and chest x-ray (CXR) were performed. High-resolution computed tomography (HRCT) was performed only in patients who had abnormal results in clinical examination, PFT, or CXR. Overall, 50 patients had normal CXR (83.3%) and 10 patients (16.7%) had abnormal CXR, including reticulonodular (3.3%), atelectasis (3.3%), and lucency (3.3%). Of the 14 cases that were HRCT, only 8 (57.1%) had abnormal lung CT scans. The Pulmonary Function Test (PFT) was taken from all patients, and 15 (25%) patients had abnormal results, 11 (18.3%) had a restrictive pattern, and 4 (6.7%) had an obstructive pattern. The incidence of lung involvement in patients with AS in this study is similar to that of other studies (16%); in most cases, the lung involvement is of the restrictive pattern. Lung involvement in these patients may be asymptomatic.
- 7 May 2014
- Published by Springer Nature in Rheumatology International
- Vol. 34 (12) , 1691-1699
Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement—a retrospective study
The aim of this study was to evaluate efficacy of azathioprine (AZA) and cyclophosphamide (CYC) as a therapeutic regimen for interstitial lung disease associated with systemic sclerosis (SSc). Thirty-six selected patients included in this retrospective cohort and received one of the two drugs; the first group consists of 15 patients who were treated with AZA (1.5–2 mg/kg/day) and the second group with 21 patients received oral CYC (up to 2 mg/kg/day). Both groups received additional low dose of prednisolone (≤10 mg) for 6 months. Forced vital capacity (FVC), diffusion lung capacity for carbon monoxide (DLCO) and skin score were assessed as outcome measures. Modified Rodnan skin score (mRSS), pulmonary function test and DLCO were evaluated at entry and at the end of study after 12 months. The mean (SD) FVC percentages obtained at baseline and post-treatment in AZA-treated patients were 62.8 ± 9.8 and 71.1 ± 20.9 with mean difference of FVC% +7.6 ± 13.1, p = 0.05, and in CYC-treated patients 59.5 ± 10.7, 63.1 ± 16.2 and +2.9 ± 11.5, respectively, p = 0.19. Baseline and post-treatment DLCO% in AZA-treated patients were 61.4 ± 25.8 and 76.7 ± 24.0 with mean difference of +15.0 ± 14.5, respectively, p = 0.01. In CYC-treated patients, those measures were 67.7 ± 27.5 and 60.0 ± 22.9 with mean difference of −8.0 ± 23.7 (p = 0.12). Following 12 months of treatment in AZA-treated patients, mean difference of changes in mRSS was −2.9 ± 3.7 and −1.4 ± 4.5 in CYC-treated patients. Our results indicated that AZA can be effective in ameliorating or stabilizing lung function in selected SSc patient groups.
- 7 May 2014
- Published by Springer Nature in Rheumatology International
- Vol. 34 (12) , 1691-1699
Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement—a retrospective study
The aim of this study was to evaluate efficacy of azathioprine (AZA) and cyclophosphamide (CYC) as a therapeutic regimen for interstitial lung disease associated with systemic sclerosis (SSc). Thirty-six selected patients included in this retrospective cohort and received one of the two drugs; the first group consists of 15 patients who were treated with AZA (1.5–2 mg/kg/day) and the second group with 21 patients received oral CYC (up to 2 mg/kg/day). Both groups received additional low dose of prednisolone (≤10 mg) for 6 months. Forced vital capacity (FVC), diffusion lung capacity for carbon monoxide (DLCO) and skin score were assessed as outcome measures. Modified Rodnan skin score (mRSS), pulmonary function test and DLCO were evaluated at entry and at the end of study after 12 months. The mean (SD) FVC percentages obtained at baseline and post-treatment in AZA-treated patients were 62.8 ± 9.8 and 71.1 ± 20.9 with mean difference of FVC% +7.6 ± 13.1, p = 0.05, and in CYC-treated patients 59.5 ± 10.7, 63.1 ± 16.2 and +2.9 ± 11.5, respectively, p = 0.19. Baseline and post-treatment DLCO% in AZA-treated patients were 61.4 ± 25.8 and 76.7 ± 24.0 with mean difference of +15.0 ± 14.5, respectively, p = 0.01. In CYC-treated patients, those measures were 67.7 ± 27.5 and 60.0 ± 22.9 with mean difference of −8.0 ± 23.7 (p = 0.12). Following 12 months of treatment in AZA-treated patients, mean difference of changes in mRSS was −2.9 ± 3.7 and −1.4 ± 4.5 in CYC-treated patients. Our results indicated that AZA can be effective in ameliorating or stabilizing lung function in selected SSc patient groups.